Pierre Arsène has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tissue‐Specific Isolation of Hepatocyte Extracellular Vesicles From Human Plasma Enables Tissue‐Resolved Proteomic and miRNA Profiling

    by Ricardo Figueiras, Susana Vagueiro, Raissa Kay, Elnaz Persia, Roger de Alwis, Razan Hijazi, Brian Davidson, Kristine von Bargen, Pierre Arsène, Tomás Dias

    Tissue‐specific resolution remains a critical barrier in liquid biopsy for precision medicine. To address this, we developed NEXPLOR (Novel EXtracellular vesicle PopuLation Omics Revealer), an immunoaffinity platform enabling selective enrichment of circulating tissue‐specific extracellular vesicles (TS‐EVs), demonstrated here for liver‐derived hepatocyte‐EVs (h‐EVs). Through in silico discovery and orthogonal antibody validation across tissues, we identified a four‐marker panel (ASGR1, ASGR2, TFR2, SLCO1B1) that selectively enriched hepatocyte EVs without co‐capturing the dominant platelet‐ and leukocyte‐EV background. In a clinical cohort of hepatocellular carcinoma (HCC), non‐cancer cirrhosis and healthy donors, NEXPLOR recovered 57% more proteins than bulk EV isolation, with greater reproducibility. By restoring tissue context, h‐EVs exposed liver biology that bulk EVs miss, spanning three levels: metabolic pathways (carbon metabolism, HIF‐1α signalling, ferroptosis), HCC‐defining proteins (PGD, H2AZ1, PRDX5), and progression‐tracking candidates (CFB, PCSK9). Small RNA sequencing detected five miRNAs upregulated in HCC versus cirrhosis h‐EVs, against 21 in bulk EVs (no overlap); yet only the h‐EV miRNAs mapped to HCC‐relevant signalling, and hepatocyte‐regulatory miR‐124‐3p appeared exclusively in h‐EVs. Together, these results establish tissue‐specific EV enrichment as a route to more actionable, multi‐omic liquid biopsies in HCC, cirrhosis and other diseases in urgent need of non‐invasive biomarkers for patient diagnosis, monitoring and stratification.

  • Open Access

    Organ-specific isolation of hepatocyte extracellular vesicles from human plasma enables tissue-resolved proteomic and miRNA profiling

    by Ricardo Figueiras, Susana Vagueiro, Raissa Kay, Elnaz Persia, Roger de Alwis, Razan Hijazi, Brian Davidson, Raquel Sanches-Kuiper, Pierre Arsène, Tomás Dias

    Tissue-specific resolution remains a key limitation in liquid biopsy to achieve the highest accuracy for precision medicine. To address this limitation, we developed NEXPLOR (Novel EXtracellular vesicle PopuLation and Omics Revealer), a magnetic bead-based platform enabling selective immuno-isolation of tissue-derived EVs. Focusing on hepatocyte-derived EVs (h-EVs), we demonstrate NEXPLOR’s specificity and sensitivity in capturing rare EV subpopulations directly from human plasma. Using in silico tissue marker discovery, we identified and validated a TOP4 capture antibody panel (ASGR1, ASGR2, TFR2, SLCO1B1) for h-EV isolation through an ultrasensitive orthogonal method (O-NEXOS). Applied to liver disease using clinical plasma samples, NEXPLOR enabled deeper and more reproducible proteomic profiling compared to matched bulk EVs, revealing liver-specific and disease-relevant pathways, including ferroptosis, HIF-1α signaling, and central carbon metabolism in cancer. Moreover, small RNA sequencing uncovered a reduced but highly informative set of miRNAs, including miR-124-3p and miR-23b-3p , differentially expressed in hepatocellular carcinoma (HCC) compared to cirrhosis, and undetectable in bulk EVs. These molecular signatures suggest disease state based on real-time hepatocyte biology. Our findings establish NEXPLOR as a robust platform for tissue-specific EV capture, enabling tissue-resolved, multi-omic biomarker discovery. This opens new frontiers in early disease detection, longitudinal monitoring, and AI-powered biomarker discovery for precision medicine.


  • Open Access

    EV products obtained from iPSC-derived MSCs show batch-to-batch variations in their ability to modulate allogeneic immune responses in vitro

    by Tobias Tertel, Robin Dittrich, Pierre Arsène, Arne Jensen, Bernd Giebel

    Mesenchymal stromal cells (MSCs) have demonstrated therapeutic potential in diverse clinical settings, largely due to their ability to produce extracellular vesicles (EVs). These EVs play a pivotal role in modulating immune responses, transforming pro-inflammatory cues into regulatory signals that foster a pro-regenerative milieu. Our previous studies identified the variability in the immunomodulatory effects of EVs sourced from primary human bone marrow MSCs as a consistent challenge. Given the limited proliferation of primary MSCs, protocols were advanced to derive MSCs from GMP-compliant induced pluripotent stem cells (iPSCs), producing iPSC-derived MSCs (iMSCs) that satisfied rigorous MSC criteria and exhibited enhanced expansion potential. Intriguingly, even though obtained iMSCs contained the potential to release immunomodulatory active EVs, the iMSC-EV products displayed batch-to-batch functional inconsistencies, mirroring those from bone marrow counterparts. We also discerned variances in EV-specific protein profiles among independent iMSC-EV preparations. Our results underscore that while iMSCs present an expansive growth advantage, they do not overcome the persistent challenge of functional variability of resulting MSC-EV products. Once more, our findings accentuate the crucial need for batch-to-batch functional testing, ensuring discrimination of effective and ineffective MSC-EV products for considered downstream applications.


  • Open Access

    An electro-optical bead-nanochip technology for the ultrasensitive and multi-dimensional detection of small extracellular vesicles and their markers

    by Tomás Dias, Ricardo Figueiras, Susana Vagueiro, Renato Domingues, Yu-Hsien Hung, Elnaz Persia, Pierre Arsène

    Small extracellular vesicles (sEVs), including exosomes, are enriched in multiomics information mirroring their parental cells. They have been investigated in health and disease and utilised in several applications from drug discovery to diagnostics. In disease diagnostics, sEVs can be sampled via a blood draw, enabling the convenient liquid biopsy of the tissue they originate from. However, few applications with sEVs have been translated into clinical practice. We developed a Nanoparticle EXOsome Sensing (NEXOS) technology, for the ultrasensitive and multi-dimensional detection of sEVs. NEXOS comprises two methods: a novel nanoelectronics method, E-NEXOS, and a high-throughput optical detection method, O-NEXOS. Both methods share the same steps for the immunocapture and antibody-labelling of sEVs and can be combined to derive differentiated detection parameters. As a proof of concept, we show the analytical detection and sensitivity of these methods in detecting pre-prepared cancer cell-derived CD9 + CD81 + and CD9 + HER2 + sEVs. Both sEV populations were diluted in PBS and spiked in processed plasma. We also provide a novel approach for the determination of target sEVs (TEVs), target epitopes in sEVs (TEPs), and epitopes per target sEV, as yet unseen from current and emerging technologies. Further, we demonstrate the higher sensitivity of O-NEXOS compared to the gold standard techniques, as well as demonstrating that E-NEXOS possesses commensurate sensitivity whilst only being powered by 36 nanogap-based sensors per nanochip. Finally, this manuscript lays the groundwork for a scalable electronics miniaturization of E-NEXOS nanochip with millions of nanogap-based sensors for the translation of NEXOS into standard clinical practice.


  • Open Access

    Lessons for SARS-CoV-2 Study (COVID-19 Disease) From Its Exosome Relatives

    by Pierre Arsene

    Our first modern global pandemic is caused by a nanosized lipid vesicle, called SARS-CoV-2. Its molecular structure and biogenesis have remarkable similarities with Extracellular Vesicles (EVs, most notably exosomes) that are constantly shed by all cells during their life. Their resemblance may not be a coincidence. Growing body of evidence has shown that EVs have significant roles in various biological processes, including viral infection, transmission and anti-viral response. Drawing comparison with the virus might shed light on how we could fight the COVID-19 disease. This may include novel EV research and diagnostics technologies as well as novel EV-based treatments.